Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 22;10(1):10122.
doi: 10.1038/s41598-020-67272-3.

Emergent cholecystectomy in patients on antithrombotic therapy

Affiliations

Emergent cholecystectomy in patients on antithrombotic therapy

Masashi Yoshimoto et al. Sci Rep. .

Abstract

The Tokyo Guidelines 2018 (TG18) recommend emergent cholecystectomy (EC) for acute cholecystitis. However, the number of patients on antithrombotic therapy (AT) has increased significantly, and no evidence has yet suggested that EC should be performed for acute cholecystitis in such patients. The aim of this study was to evaluate whether EC is as safe for patients on AT as for patients not on AT. We retrospectively analyzed patients who underwent EC from 2007 to 2018 at a single center. First, patients were divided into two groups according to the use of antithrombotic agents: AT; and no-AT. Second, the AT group was divided into three sub-groups according to the use of single antiplatelet therapy (SAPT), double antiplatelet therapy (DAPT), or anticoagulant with or without antiplatelet therapy (AC ± APT). We then evaluated outcomes of EC among all four groups. The primary outcome was 30- and 90- day mortality rate, and secondary outcomes were morbidity rate and surgical outcomes. A total of 478 patients were enrolled (AT, n = 123, no-AT, n = 355) patients. No differences in morbidity rate (6.5% vs. 3.7%, respectively; P = 0.203), 30-day mortality rate (1.6% vs. 1.4%, respectively; P = 1.0) or 90-day mortality rate (1.6% vs. 1.4%, respectively; P = 1.0) were evident between AT and no-AT groups. Between the no-AT and AC ± APT groups, a significant difference was seen in blood loss (10 mL vs. 114 mL, respectively; P = 0.017). Among the three AT sub-groups and the no-AT group, no differences were evident in morbidity rate (3.7% vs. 8.9% vs. 0% vs. 6.5%, respectively; P = 0.201) or 30-day mortality (1.4% vs. 0% vs. 0% vs. 4.3%, respectively; P = 0.351). No hemorrhagic or thrombotic morbidities were identified after EC in any group. In conclusion, EC for acute cholecystitis is as safe for patients on AT as for patients not on AT.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Multiple comparisons of characteristics and perioperative outcomes for no-AT, SAPT, DAPT, and AC±APT groups. (A) Fisher’s exact test and Bonferroni correction were used for comparing categorical variables. (B) Continuous variables were analyzed using the Mann-Whitney U test and multiple comparisons were performed using the Kruskal-Wallis and Steel-Dwass tests.

References

    1. Yokoe M, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos) J. Hepatobiliary Pancreat. Sci. 2018;25:41–54. doi: 10.1002/jhbp.515. - DOI - PubMed
    1. Okamoto K, et al. Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis. J. Hepatobiliary Pancreat. Sci. 2018;25:55–72. doi: 10.1002/jhbp.516. - DOI - PubMed
    1. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013;368:2113–2124. doi: 10.1056/NEJMra1206531. - DOI - PubMed
    1. Kolla SB, et al. Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a prospective randomized trial. Surg. Endosc. 2004;18:1323–1327. doi: 10.1007/s00464-003-9230-6. - DOI - PubMed
    1. Lau H, Lo CY, Patil NG, Yuen WK. Early versus delayed-interval laparoscopic cholecystectomy for acute cholecystitis: a metaanalysis. Surg. Endosc. 2006;20:82–87. doi: 10.1007/s00464-005-0100-2. - DOI - PubMed

Substances